Phathom Pharmaceuticals, Inc. — Form 8-K
Reporting date: September 29, 2026. The filing reports a clinical-development update; it does not include financial results for a quarterly or annual reporting period.
Business context and event
Phathom announced that patient screening has begun in pHalcon-NERD-302, a registrational Phase 3 study of investigational as-needed VOQUEZNA (vonoprazan) 10 mg tablets for adults with non-erosive gastroesophageal reflux disease (NERD). The company says the study builds on previously reported positive Phase 2 results. If successful, it is intended to support a potential regulatory submission for a label expansion.
- The study is randomized, double-blind, placebo-controlled, and planned to enroll approximately 500 adults at about 80 U.S. sites.
- After a four-week open-label run-in of once-daily VOQUEZNA, eligible patients will be randomized 1:1 to as-needed VOQUEZNA or placebo for 24 weeks.
- The primary endpoint at Week 12 is the percentage of heartburn episodes with complete relief within two hours and sustained relief for 24 hours after dosing.
- Topline results are expected in the first quarter of 2028.
Financial metrics and comparison
This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It contains no comparable-period financial data, so financial changes versus a prior period cannot be assessed from this filing.
Outlook, risks, and contingencies
The stated topline-results timing and potential label-expansion submission are forward-looking and subject to risks. The filing identifies possible delays in site activation or enrollment, study-conduct or data-analysis issues, results that are negative, mixed, inconclusive, or fail to replicate Phase 2, regulatory authorities finding results insufficient, safety or tolerability concerns, competition, manufacturing or technical problems, and future cash needs that could change the company’s plans. Even positive results would not ensure a submission or approval.
Key facts for investors to verify
- Progress of site activation, enrollment, and study conduct relative to the expected timeline.
- Whether the study’s primary endpoint and other results support the anticipated as-needed treatment benefit.
- Any safety, tolerability, manufacturing, or competitive developments affecting the program.
- Whether Phathom ultimately pursues a label expansion and whether regulators consider the evidence sufficient.
- Current cash needs and financial position in the company’s other SEC filings; this 8-K does not provide those details.